RALLYBIO CORPORATION Deferred Offering Costs
RALLYBIO CORPORATION (RLYB) had Deferred Offering Costs of $0 as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2025-03-13
- 2024-12-31: Deferred Offering Costs $0.00.
- 2023-12-31: Deferred Offering Costs $0.00.
- 2022-12-31: Deferred Offering Costs $100.00K.
- 2021-12-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2022-12-31 | $100.00K 10-K · filed 2024-03-12 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 |
| 2021-06-30 | $2.40M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |